A federal judge in New Jersey ruled against Johnson & Johnson and Bristol Myers Squibb in their legal challenge against the Inflation Reduction Act's provision requiring them to negotiate prices for their blockbuster blood clot prevention drugs with the U.S. government's Medicare program. The court dismissed the companies' claims, including a 'freedom of speech' argument and a Takings Clause argument, marking a significant victory for the Biden administration. This decision confirms the constitutional validity of the IRA's drug negotiation program and is part of a series of legal setbacks for the pharmaceutical industry.